Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Study to Demonstrate the Efficacy and Safety of RG1068 (Synthetic Human Secretin)- Enhanced Magnetic Resonance Cholangiopancreatography (MRCP) in the Evaluation of Subjects With a History of Acute or Acute Recurrent Pancreatitis

NCT00660335 is registered in ClinicalTrials.gov with Repligen Corporation as lead sponsor.

NCT NCT00660335
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00660335 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Study to Demonstrate the Efficacy and Safety of RG1068 (Synthetic Human Secretin)- Enhanced Magnetic Resonance Cholangiopancreatography (MRCP) in the Evaluation of Subjects With a History of Acute or Acute Recurrent Pancreatitis
Lead sponsor
Repligen Corporation
Phase
Phase 3
Overall status
Completed
Start date
March 31, 2008
Completion date
October 31, 2009
Enrollment
258 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatitis